HC Wainwright Estimates Cibus’ Q3 Earnings (NASDAQ:CBUS)

Cibus, Inc. (NASDAQ:CBUS) – Equities research analysts at HC Wainwright dropped their Q3 2026 earnings per share estimates for shares of Cibus in a research report issued on Friday, August 14th. HC Wainwright analyst A. Dayal now anticipates that the company will post earnings per share of ($0.27) for the quarter, down from their prior forecast of ($0.24). The consensus estimate for Cibus’ current full-year earnings is ($1.05) per share. HC Wainwright also issued estimates for Cibus’ Q4 2026 earnings at ($0.25) EPS, FY2026 earnings at ($1.13) EPS, FY2027 earnings at ($1.07) EPS and FY2028 earnings at ($0.50) EPS.

CBUS has been the topic of a number of other research reports. Wall Street Zen raised shares of Cibus from a “sell” rating to a “hold” rating in a research report on Saturday, July 25th. Weiss Ratings downgraded shares of Cibus from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, June 29th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $9.00.

Cibus Trading Down 5.6%

CBUS opened at $1.67 on Tuesday. The business has a 50 day moving average of $1.66 and a 200-day moving average of $1.97. The stock has a market capitalization of $127.47 million, a price-to-earnings ratio of -1.01 and a beta of 1.61. Cibus has a 1-year low of $1.09 and a 1-year high of $4.19.

Cibus (NASDAQ:CBUS) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.10). Cibus had a negative return on equity of 287.03% and a negative net margin of 2,258.89%.The business had revenue of $0.99 million during the quarter, compared to the consensus estimate of $1.70 million.

Hedge Funds Weigh In On Cibus

Large investors have recently added to or reduced their stakes in the company. Weiss Asset Management LP bought a new stake in shares of Cibus in the 1st quarter worth approximately $1,758,000. Geode Capital Management LLC increased its position in shares of Cibus by 4.7% during the fourth quarter. Geode Capital Management LLC now owns 275,180 shares of the company’s stock valued at $479,000 after purchasing an additional 12,467 shares during the period. Certior Financial Group LLC increased its position in shares of Cibus by 46.7% during the fourth quarter. Certior Financial Group LLC now owns 271,164 shares of the company’s stock valued at $472,000 after purchasing an additional 86,378 shares during the period. Prescott Group Capital Management L.L.C. bought a new stake in shares of Cibus during the fourth quarter valued at approximately $345,000. Finally, Jane Street Group LLC acquired a new position in shares of Cibus in the second quarter valued at $207,000. Institutional investors and hedge funds own 33.81% of the company’s stock.

Cibus Company Profile

Cibus, Inc is a biotechnology company specializing in precision gene editing for agricultural applications. Leveraging its proprietary Rapid Trait Development System (RTDS), Cibus develops improved crop traits without the introduction of foreign DNA. The company’s platform enables targeted modifications to plant genomes, allowing for enhanced disease resistance, herbicide tolerance and yield optimization in key row crops.

The company’s core business centers on trait development services and licensing partnerships.